mass spectrometry is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2025-08-23. Numbers and descriptions here follow the published literature rather than marketing material.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
| Property | Value | Notes |
|---|---|---|
| Common name | AOD-9604 | Development code used in scientific literature. |
| Chemical class | Synthetic peptide | Fragment of human growth hormone. |
| Amino acid length | 16 residues | Matches hGH region 176-191. |
| Appearance | White to off-white powder | Typical lyophilized peptide solid. |
| Solubility | Soluble in water | Dissolves in aqueous media; exact behavior depends on salt form. |
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
== Animal models == Mice genetically engineered to lack glutathione peroxidase 1 (Gpx1−/− mice) are grossly phenotypically normal and have normal lifespans, indicating this enzyme is not critical for life. However, Gpx1−/− mice develop cataracts at an early age and exhibit defects in muscle satellite cell proliferation. Gpx1 −/− mice showed up to 16 dB higher auditory brainstem response (ABR) thresholds than control mice. After 110 dB noise exposure for one hour, Gpx1 −/− mice had up to 15 dB greater noise-induced hearing loss compared with control mice." Mice with knockouts for GPX3 (GPX3−/−) or GPX2 (GPX2−/−) also develop normally However, glutathione peroxidase 4 knockout mice die during early embryonic development. Some evidence, though, indicates reduced levels of glutathione peroxidase 4 can increase life expectancy in mice.
Rauwolscine, also known as isoyohimbine, α-yohimbine, and corynanthidine, is an alkaloid found in various species within the genera Rauvolfia and Corynanthe (including Pausinystalia). It is a stereoisomer of yohimbine. Rauwolscine is a central nervous system stimulant, a local anesthetic and a vague aphrodisiac. Rauwolscine acts predominantly as a α2-adrenergic receptor antagonist. It has also been shown to function as a 5-HT1A receptor partial agonist and 5-HT2A and 5-HT2B receptor antagonist.
The ready palpability of the breast-cancer tumor(s) is consequent to breast tissue thinning by compression, innately in smaller breasts a priori (because they have lesser tissue volumes), and that the implant serves as a radio-opaque base against which a cancerous tumor can be differentiated.
== Reception and influence == A chapter in Hervé Le Tellier's novel Enough About Love pays homage to Edouard Levé, who appears as the character Hugues Léger, and to his book Autoportrait, the introspective and fragmentary style of which is imitated in an extract of a book titled Definition. Gérard Gavarry's book Expérience d'Edward Lee, Versailles (P.O.L., 2009) takes as its inspiration one hundred photos by Levé.
Sources: en.wikipedia.org
== Popular culture == Tetrodotoxin serves as a plot device for characters to fake death, as in the films Hello Again (1987), The Serpent and the Rainbow (1988), The A-Team (2010), Captain America: The Winter Soldier (2014), and War (2019), and in episodes of Jane the Virgin, Miami Vice (1985), Nikita, MacGyver (season 7, episode 6, where the antidote is Datura stramonium leaf), CSI: NY (season 4, episode 9, "Boo"), and Chuck. In Law Abiding Citizen (2009), Alex Cross (2012), and Send Help (2026), paralysis is presented as a method of assisting torture. The toxin was also referenced in "synthetic form" in season 1, episode 2, of the series "FBI". The toxin is used as a weapon in both the second season of Archer, in Covert Affairs and in the Inside No. 9 episode "The Riddle of the Sphinx". In Columbo, episode 2 of season 7, fugu is used to kill the antagonist's victim. In The Apothecary Diaries light novel, as well as the respective manga and anime adaptations, fugu toxin is encountered across multiple mystery arcs. Based on the presumption that tetrodotoxin is not always fatal, but at near-lethal doses can leave a person extremely unwell with the person remaining conscious, tetrodotoxin has been alleged to result in zombieism, and has been suggested as an ingredient in Haitian Vodou preparations. This idea first appeared in the 1938 non-fiction book Tell My Horse by Zora Neale Hurston in which there were multiple accounts of purported tetrodotoxin poisoning in Haiti by a voodoo sorcerer called the bokor.
biosynthesis from the sulfur amino acids (e.g., cysteine); active uptake by a taurine transporter; and the extent of its release from cells by a "volume-sensitive leak pathway". Taurine is a major constituent of bile, and can be found in the large intestine. Its concentrations in land plants are low or undetectable, but up to a substantial wet weight has been found in algae.
Conformations are the same in solution and when adsorbed. Diastereomers bind to surfaces (silica gel in normal phase chromatography) mainly with hydrogen bonding. Significant resolution of diastereomers is only expected when molecules can adsorb to silica through two contact points (two hydrogen bonds). This interaction can be perturbed by substituents. Diastereomers with bulky substituents on the alpha carbon (R2) and on the nitrogen (R1) can shield the hydrogen bonding with the surface, thus the molecule will be eluted before similar molecules with smaller substituents. Helmchen's postulates have been proven to be applicable to other functional groups such as: carbamates, esters, and epoxides.
Sources: en.wikipedia.org
=== Allegations and lawsuit against the Mirror Group === In October 1991, Galloway tabled a motion in the House of Commons expressing concern at the allegations against news publisher Mirror Group Newspapers put forward in Seymour Hersh's recently published book, The Samson Option: Israel's Nuclear Arsenal and American Foreign Policy. Hersh alleged that the Daily Mirror's foreign editor, Nicholas Davies, was involved in weapons sales to Iran and had given the whereabouts of Mordechai Vanunu to Mossad. Mossad sought to capture Vanunu due to his role as a whistleblower of Israeli nuclear operations, and later "lured [him] out of Britain to Italy", where he "was kidnapped, drugged and returned to Israel". Galloway's motion also called upon Mirror Group's owner, Robert Maxwell, to appoint a tribunal to investigate the allegations and the potential involvement of foreign intelligence in the publishing group. As the motion was signed under parliamentary privilege, other news outlets could report on it without worrying about legal repercussion, as Maxwell was known for litigiousness. Following this, the Daily Mirror published a "vitriolic" front-page editorial against Galloway, accusing him of abusing parliamentary privilege and of being motivated by links to anti-Israel terrorist groups. Galloway sued for libel and was awarded a public apology and substantial undisclosed damages from the Mirror Group.
=== Retinol concentrations are nonsensitive indicators === Assessing vitamin A status in persons with sub-toxicity or toxicity is complicated because serum retinol concentrations are not sensitive indicators in this range of liver vitamin A reserves. The range of serum retinol concentrations under normal conditions is 1–3 μmol/L and, because of homeostatic regulation, that range varies little with widely disparate vitamin A intakes.
biomolecular gradient Any difference in the concentration of biomolecules between two spaces within a biological system, whether intracellular, extracellular, across a membrane, or between different cells or different parts of a tissue or organ system. Gradients of one kind or another drive virtually all biochemical processes occurring within and between cells, as natural systems tend to move toward a thermodynamic equilibrium where concentrations are uniformly distributed in all spaces and no gradients exist. Gradients thus cause chemical reactions to occur in particular directions, which can be used by cells to accomplish essential biological functions, including metabolic energy transfer, signal transduction, and movement of ions and solutes into and out of cells and organelles. It is often necessary for cells to continuously regenerate gradients such as membrane potentials in order to permit these processes to continue.
Most democratic socialist scholars and analysts have been sceptical of Chavismo and some of Latin America's other ruling parties as examples of democratic socialism. While citing their progressive role, they argue that the appropriate label for these governments is populism rather than socialism due to their authoritarian characteristics and occasional cults of personality. On socialist development in Venezuela, Chávez argued in 2012 that, with the second government plan (Plan de la Patria), "socialism has just begun to implant its internal dynamism among us" whilst acknowledging that "the socio-economic formation that still prevails in Venezuela is capitalist and rentier." This same thesis is defended by Maduro, who acknowledges that he has failed in the development of the productive forces while admitting that "the old model of corrupt and inefficient state capitalism" typical of traditional Venezuelan oil rentism has contradictorily combined with a statist model that "pretends to be a socialist." There was a resurgence of the "pink tide" in the late 2010s. In Mexico, Andrés Manuel López Obrador of the National Regeneration Movement was elected in a landslide victory in the 2018 Mexican general election. Many of his policy proposals include traditionally labour based and social democratic reforms.
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone. It corresponds to the C-terminal region known as hGH 176-191 and is studied for metabolic effects. It is not an approved therapeutic drug.
No. It contains only a small portion of the human growth hormone sequence. The full hormone has 191 amino acids and many additional actions that the fragment does not share.
The name refers to the amino acid positions in the human growth hormone chain. The fragment spans residues 176 through 191 at the C-terminal end. This naming convention helps distinguish it from full-length hGH.
No. It is not approved as a therapeutic drug by major regulators. It is sold for research purposes in many settings, which is not the same as clinical approval.